91桃色

Pediatric oncology; Emerging biomarkers; Early detection; Precision medicine; Liquid biopsy; Circulating tumor DNA

Introduction

Pediatric oncology remains a critical area of medical research, with early detection and precise treatment being essential for improving survival rates and quality of life in young patients [1]. Unlike adult cancers, pediatric malignancies often have unique genetic and molecular characteristics that require specialized diagnostic and therapeutic approaches. Traditional diagnostic methods, including imaging and histopathological analysis, have limitations in detecting cancer at an early stage or predicting treatment response accurately [2].

Emerging biomarkers have revolutionized the field of pediatric oncology by providing new avenues for early diagnosis, prognosis, and therapy monitoring. These biomarkers, derived from genetic, epigenetic, proteomic, and metabolomic studies, offer valuable insights into tumor biology and patient-specific treatment responses. Liquid biopsy techniques, such as the detection of circulating tumor DNA (ctDNA) and extracellular vesicles, have further advanced non-invasive cancer detection and monitoring [3]. This review explores the latest developments in pediatric oncology biomarkers, emphasizing their role in enhancing diagnostic precision and guiding targeted therapies. By integrating these novel biomarkers into clinical practice, healthcare providers can move toward more personalized treatment strategies, ultimately improving outcomes for pediatric cancer patients [4].

Discussion

The integration of emerging biomarkers into pediatric oncology has transformed cancer diagnosis, prognosis, and treatment response evaluation. Advances in genomic, proteomic, and metabolomic research have facilitated the identification of biomarkers that can predict disease progression, treatment resistance, and relapse risk [5]. Genetic markers, such as mutations in TP53, MYCN amplification in neuroblastoma, and ETV6-RUNX1 fusion in acute lymphoblastic leukemia (ALL), have been instrumental in refining risk stratification and guiding treatment decisions. Epigenetic biomarkers, including DNA methylation and histone modifications, have provided new insights into tumor biology and therapeutic targets [6]. Aberrant methylation patterns have been linked to various pediatric malignancies, such as Wilms tumor and medulloblastoma, highlighting their potential as diagnostic and prognostic tools. Proteomic and metabolomic studies have also uncovered novel biomarkers that offer real-time assessments of tumor metabolism and response to therapy, further supporting precision medicine approaches [7].

Liquid biopsy, particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), has emerged as a non-invasive alternative to traditional tissue biopsies. This approach enables real-time monitoring of tumor dynamics, treatment effectiveness, and minimal residual disease (MRD) detection, reducing the need for invasive procedures [8]. Moreover, immunological biomarkers, such as cytokines and immune checkpoint molecules, are being explored to enhance immunotherapy strategies in pediatric oncology. Despite these advancements, several challenges remain in translating biomarker discoveries into routine clinical practice [9]. The heterogeneity of pediatric cancers, small patient populations, and the need for standardized validation methods pose significant barriers. Additionally, ethical considerations surrounding genetic and molecular testing in children must be carefully addressed. Future research should focus on large-scale multicenter studies, improved assay sensitivity, and the integration of multi-omics approaches to enhance biomarker reliability and applicability. Overall, the continued exploration and validation of emerging biomarkers hold great promise for improving early detection, risk assessment, and personalized treatment strategies in pediatric oncology. By bridging the gap between research and clinical application, these biomarkers can contribute to better patient outcomes and more effective therapeutic interventions [10].

Conclusion

Emerging biomarkers have revolutionized pediatric oncology by enhancing early detection, risk stratification, and treatment response assessment. Advances in genetic, epigenetic, proteomic, and metabolomic research have led to the identification of biomarkers that provide critical insights into tumor biology and therapeutic targets. Liquid biopsy techniques, particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), offer non-invasive alternatives for real-time monitoring of disease progression and treatment efficacy. Despite these advancements, challenges such as cancer heterogeneity, small patient cohorts, and the need for standardized validation methods remain barriers to clinical translation. Addressing these challenges through large-scale multicenter studies, improved assay sensitivity, and multi-omics integration will be essential for optimizing biomarker-driven strategies. Future research should focus on refining biomarker-based diagnostic and therapeutic approaches to enhance personalized medicine in pediatric oncology. By incorporating validated biomarkers into routine clinical practice, healthcare providers can improve patient outcomes, minimize treatment-related toxicity, and advance precision medicine in pediatric cancer care.

References

1. Payne JD, Stickgold R, Swanberg K, Kensinger EA (2008) . Psychol Sci 19: 781-788.

, ,

2. Li W. Ma L, Yang G, Gan WB (2017) . Nat Neurosci 20: 427-437.

, ,

3. Le Bom O (2020) . Sleep Medicine 70: 6-16.

, ,

4. Roberts RE, Duong HT (2014) Sleep 37: 239-244.

, ,

5. Sejbuk M, Mironczuk-Chodakowska I, Witkowska AM (2022) . Nutrients 14: 1912.

, ,

6. de Mendonça FMR, de Mendonça GPRR, Souza LC, Galvão LP, Paiva HS, et al. (2023) . CNS Neurol Disord Drug Targets 22: 172-179.

, ,

7. de Aquino Junior AE, Rodrigues TZ, Garcia V, Simão G, Carbinatto FM, et al. (2022) Conjugated and Synergistic Therapies in the treatment of Covid 19 Dysfunction - Pain, Weakness, Parestheria, Respiratory Condition, Memory, Olfactory and Taste: Case Series. J Nov Physiother 12: 545.
8. de Aquino Junior AE, Carbinatto FM, Franco DM, Silva JD, Bruno A, et al. (2021) The Laser and Ultrasound: The Ultra Laser like Efficient Treatment to Fibromyalgia by Palms of Hands: Comparative Study. J Nov Physiotherapies 11: 447.
9. de Aquino Junior AE, Carbinatto FM, Rodrigues TZ, Garcia V, et al. (2023) The Regulatory Action of Fibro fog: Pain, Quality of Life, Sleep, Anxiety and Depression observed after 42 Months of Treatment: A Case Report. J Nov Physiother 13: 2.
10. de Aquino Junior AE, Carbinatto FM, Tomaz CDSR, Bagnato VS (2022) Photosonic treatment and Fibromyalgia: The Effect on Brain Compliance-Case Report. J Nov Physiother 12: 510.